Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine
Nycomed and Norgine sign a Licence Agreement for MOVIPREP® in Russia and the Commonwealth of Independent States (CIS)
Nycomed and Norgine, a European
specialty pharmaceutical company, today announced that they have entered into a
licensing agreement that gives Nycomed the exclusive rights to commercialise
MOVIPREP, the worlds leading bowel cleansing brand, in Russia, Armenia,
Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia,
Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.
Moviprep is an osmotic laxative for bowel cleansing prior to any clinical procedure requiring a clean bowel, such as colonoscopy. MOVIPREP will be subject to regulatory review and approval and Nycomed will conduct the necessary steps for approval. Financial details of the agreement were not disclosed.
Enimloetud
Viimased uudised
Hetkel kuum
Liitu uudiskirjaga
Telli uudiskiri ning saad oma postkasti päeva olulisemad uudised.
Tagasi Meditsiiniuudised esilehele